Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia

Venetoclax (Venclyxto, Abbvie) in combination with obinutuzumab is indicated for 'the treatment of adult patients with previously untreated chronic lymphocytic leukaemia'.

The dosage schedule is available in the summary of product characteristics for venetoclax.

A 112-pack of 100-mg venetoclax tablets costs £4,789.47 (excluding VAT; BNF online, accessed October 2025).

Abbvie has a commercial arrangement. This makes venetoclax available to the NHS with a discount. The size of the discount is commercial in confidence. It is Abbvie's responsibility to let relevant NHS organisations know details of the discount.

The price of obinutuzumab is £3,312 per 1,000-mg vial (excluding VAT; BNF online, accessed October 2025).

Roche has a commercial arrangement. This makes obinutuzumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is Roche's responsibility to let relevant NHS organisations know details of the discount.

For information, Abbvie's Carbon Reduction Plan for UK carbon emissions is published on their webpage on sustainable community impact.

For information, Roche's Carbon Reduction Plan for UK carbon emissions is published on their webpage on sustainability.